Research programme: interferon beta-human serum albumin fusion protein - Teva Pharmaceutical Industries
Alternative Names: TV-1390Latest Information Update: 16 Jul 2016
At a glance
- Originator Teva Pharmaceutical Industries
- Class Albumins; Interferons; Recombinant fusion proteins
- Mechanism of Action Interferon beta stimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
Highest Development Phases
- No development reported Multiple sclerosis
Most Recent Events
- 16 Jul 2016 No recent reports of development identified for preclinical development in Multiple-sclerosis in Israel (SC)
- 16 Sep 2010 Preclinical trials in Multiple sclerosis in Israel (SC)